46 Biggest Movers From Yesterday
Gainers
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday.
36 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.
JNJ’s Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma
Janssen, a unit of Johnson & Johnson (NYSE: JNJ), posted
Why Are Legend Biotech Shares Gaining Today?
Legend Biotech Corporation’s (NASDAQ:LEGN) collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese Ministry of Health, Labour and Welfare (MHLW)…
Legend Biotech Reports Submission Of New Drug Application To Japanese Regulatory Authority For CAR-T Therapy Cilta-Cel
Submission based on data from pivotal CARTITUDE-1 trial
SOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ:LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel
Legend Biotech Highlights Submission Of New Drug Application To Japanese Regulatory Authority For B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor-T Cell Therapy For Treatment Of Adults With Relapsed, Refractory Multiple Myeloma
Legend Biotech Corporation (NASDAQ:LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese
80 Biggest Movers From Yesterday
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss.
53 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss.
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes.
PDUFA dates are key binary events for biotech stocks that can move the needle in a big way. These are the dates by which the Food and Drug Administration is required to announce its decision regarding approvability/non-approvability of drugs.